论文部分内容阅读
目的:探讨恶性血液病合并真菌感染的临床治疗,进一步改进治疗措施和方法,减少合并真菌感染率、死亡率,提高生存率。方法:对2005年1月—2010年5月在我院经微生物学检查证实的85例恶性血液病合并真菌感染患者的临床资料进行统计分析。结果:真菌感染以白色念珠菌最为常见,占65.85%;感染部位以呼吸道为主,占87.06%;胃肠道次之,占8.24%;恶性血液病合并真菌感染无效38.82%;总有效率61.18%。结论:恶性血液病合并真菌感染,危险因素较多,临床病死率较高,抗真菌药物曲康唑或氟康唑可以作为浅部真菌感染的一线药物。
Objective: To investigate the clinical treatment of hematological malignancies complicated with fungal infection, to further improve the treatment measures and methods to reduce the combined fungal infection rate and mortality and improve the survival rate. Methods: The clinical data of 85 patients with fungal hematological malignancies confirmed by microbiological examination in our hospital from January 2005 to May 2010 were statistically analyzed. Results: The most common fungal infection was Candida albicans, accounting for 65.85%. The main respiratory tract infection was 87.06%, the second was gastrointestinal tract, accounting for 8.24%, and the third was 38.82% for malignant hematological disease complicated with fungal infection. The total effective rate was 61.18 %. CONCLUSION: Malignant hematological diseases complicated with fungal infection have more risk factors and higher clinical mortality. Antifungal drug fluconazole or fluconazole can be regarded as the first-line drug for superficial fungal infection.